Učitavanje...
Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy
In a previous study, we determined that major pathologic response (MPR) as indicated by the percentage of residual viable tumor cells predicted overall survival (OS) in patients with non‐small‐cell lung cancer (NSCLC) who received neoadjuvant chemotherapy. In this study, we assessed whether two gene...
Spremljeno u:
| Izdano u: | Cancer Med |
|---|---|
| Glavni autori: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6010873/ https://ncbi.nlm.nih.gov/pubmed/29673125 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1505 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|